These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 29971600)

  • 41. Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG.
    Ma S; Jiang W; Liu X; Lu WJ; Qi T; Wei J; Wu F; Chang Y; Zhang S; Song Y; Bai R; Wang J; Lee AS; Zhang H; Wang Y; Lan F
    Circ Res; 2021 Oct; 129(10):895-908. PubMed ID: 34525843
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular characterization of a large MYBPC3 rearrangement in a cohort of 100 unrelated patients with hypertrophic cardiomyopathy.
    Chanavat V; Seronde MF; Bouvagnet P; Chevalier P; Rousson R; Millat G
    Eur J Med Genet; 2012 Mar; 55(3):163-6. PubMed ID: 22314326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic basis of hypertrophic cardiomyopathy.
    Lind JM; Chiu C; Semsarian C
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):927-34. PubMed ID: 17173506
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes.
    Poutanen T; Tikanoja T; Jääskeläinen P; Jokinen E; Silvast A; Laakso M; Kuusisto J
    Am Heart J; 2006 Mar; 151(3):725.e1-725.e9. PubMed ID: 16504640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modelling genetic diseases for drug development: Hypertrophic cardiomyopathy.
    Santini L; Palandri C; Nediani C; Cerbai E; Coppini R
    Pharmacol Res; 2020 Oct; 160():105176. PubMed ID: 32871247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy.
    Chida A; Inai K; Sato H; Shimada E; Nishizawa T; Shimada M; Furutani M; Furutani Y; Kawamura Y; Sugimoto M; Ishihara J; Fujiwara M; Soga T; Kawana M; Fuji S; Tateno S; Kuraishi K; Kogaki S; Nishimura M; Ayusawa M; Ichida F; Yamazawa H; Matsuoka R; Nonoyama S; Nakanishi T
    Heart Vessels; 2017 Jun; 32(6):700-707. PubMed ID: 27885498
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort.
    Chen H; Li X; Liu X; Wang J; Zhang Z; Wu J; Huang M; Guo Y; Li F; Wang X; Fu L
    Orphanet J Rare Dis; 2019 Feb; 14(1):29. PubMed ID: 30732632
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Homozygous mutation of MYBPC3 associated with severe infantile hypertrophic cardiomyopathy at high frequency among the Amish.
    Zahka K; Kalidas K; Simpson MA; Cross H; Keller BB; Galambos C; Gurtz K; Patton MA; Crosby AH
    Heart; 2008 Oct; 94(10):1326-30. PubMed ID: 18467358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First identification of homozygous truncating CSRP3 variants in two unrelated cases with hypertrophic cardiomyopathy.
    Janin A; Bessière F; Chauveau S; Chevalier P; Millat G
    Gene; 2018 Nov; 676():110-116. PubMed ID: 30012424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
    Coppini R; Mazzoni L; Ferrantini C; Gentile F; Pioner JM; Laurino A; Santini L; Bargelli V; Rotellini M; Bartolucci G; Crocini C; Sacconi L; Tesi C; Belardinelli L; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Poggesi C
    Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28255011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular genetics and pathogenesis of hypertrophic cardiomyopathy.
    Marian AJ; Salek L; Lutucuta S
    Minerva Med; 2001 Dec; 92(6):435-51. PubMed ID: 11740432
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation.
    van Velzen HG; Schinkel AFL; Oldenburg RA; van Slegtenhorst MA; Frohn-Mulder IME; van der Velden J; Michels M
    Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28794111
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review of recent advances in the management of hypertrophic cardiomyopathy.
    Cao Y; Zhang PY
    Eur Rev Med Pharmacol Sci; 2017 Nov; 21(22):5207-5210. PubMed ID: 29228435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myosin-binding Protein C Compound Heterozygous Variant Effect on the Phenotypic Expression of Hypertrophic Cardiomyopathy.
    Rafael JF; Cruz FEDS; Carvalho ACC; Gottlieb I; Cazelli JG; Siciliano AP; Dias GM
    Arq Bras Cardiol; 2017 Apr; 108(4):354-360. PubMed ID: 28538763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypertrophic cardiomyopathy in man and cats.
    Maron BJ; Fox PR
    J Vet Cardiol; 2015 Dec; 17 Suppl 1():S6-9. PubMed ID: 26776595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy.
    Girolami F; Olivotto I; Passerini I; Zachara E; Nistri S; Re F; Fantini S; Baldini K; Torricelli F; Cecchi F
    J Cardiovasc Med (Hagerstown); 2006 Aug; 7(8):601-7. PubMed ID: 16858239
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic basis of end-stage hypertrophic cardiomyopathy.
    Garcia-Pavia P; Vázquez ME; Segovia J; Salas C; Avellana P; Gómez-Bueno M; Vilches C; Gallardo ME; Garesse R; Molano J; Bornstein B; Alonso-Pulpon L
    Eur J Heart Fail; 2011 Nov; 13(11):1193-201. PubMed ID: 21896538
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement.
    Burban A; Pucyło S; Sikora A; Opolski G; Grabowski M; Kołodzińska A
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686045
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline.
    Tamargo J; Tamargo M; Caballero R
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1027-1052. PubMed ID: 36062808
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The clinical features, outcomes and genetic characteristics of hypertrophic cardiomyopathy patients with severe right ventricular hypertrophy.
    Guo X; Fan C; Tian L; Liu Y; Wang H; Zhao S; Duan F; Zhang X; Zhao X; Wang F; Zhu H; Lin A; Wu X; Li Y
    PLoS One; 2017; 12(3):e0174118. PubMed ID: 28323875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.